Naproxcinod  (Synonyms: AZD 3582; HCT 3012; Nitronaproxen)

Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation^[1][2][3].

Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level^[1].
Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

347.36

C₁₈H₂₁NO₆

163133-43-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5.  [Content Brief]

  [2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35.  [Content Brief]

  [3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49.  [Content Brief]